Literature DB >> 10482939

Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation.

A Abu-Ghosh1, S Goldman, V Slone, C van de Ven, Y Suen, L Murphy, L Sender, M Cairo.   

Abstract

We investigated early immunological reconstitution and the production of circulating inflammatory mediators and their relationship to aGVHD in children during the first 100 days following unrelated UCBT. Nine patients had an underlying malignant disease (ALL, ANLL), and two, non-malignant diseases (SAA, ALD). The median age was 10 years (range: 1.25-21). Seven of 11 patients were alive by day 100, two died from regimen-related toxicity, and two died from severe aGVHD (grade >/=III). Myeloid engraftment (ANC >/=500/mm3 x 2 days) occurred at a median of 24 days (range: 14-55), while platelet engraftment (platelet count >/=20 000/mm3 untransfused x 7 days) was delayed and occurred at a median of 52 days (range: 33-95). The mean cell dose of CD34+ cells was 3.3 +/- 3.51 x 10(5)/kg, and of CD34+/CD41+ cells was 3.94 +/- 3.99 x 10(4)/kg. Acute GVHD (grade II-IV) developed in seven patients (77%), and severe aGVHD (grade III-IV) developed in five patients (55%). Serum levels of IL-2Ralpha, IL-2, IL-4, IL-7, IL-12, and IFNgamma were not significantly different between patients with grades 0-I aGVHD and patients with grades II-IV aGVHD. Evaluation of immunological reconstitution on day 90 post UCBT demonstrated an early recovery of the absolute numbers of B cells (CD19+) and NK cells (CD3-/CD56+). Immunoglobulin levels for IgG, IgM and IgA remained normal throughout the study period. PMN functional studies demonstrated normal superoxide generation, bacterial killing (BK), and chemotaxis (CTX). However, both helper (CD3+/CD4+) and suppressor (CD3+/CD8+) T cell subsets remained low during the first 100 days post UCBT with mean +/- s.e.m. values of 120 +/- 29/mm3 and 10 +/- 50/mm3, respectively (normal = 900-2860/mm3 (CD3/CD4), normal = 630-1910/mm3 (CD3/CD8)). Mitogen response studies showed low blastogenesis to PHA and PWM, with a mean c.p.m. +/- s.e.m. value of 1.7 +/- 0.67 x 10(4) for PHA (NL >/= 75 x 10(3)) and 8.42 +/- 4.1 x 10(3) for PWM (NL >/=25 x 10(3)). In conclusion, serum levels of inflammatory mediators were not predictive nor did they correlate with the severity of aGVHD. Recovery of NK cells, B cells, and PMN functions occurred within the first 90 days post transplant. However, T cell subsets, CD3+/CD4+ and CD3+/CD8+, and T cell functional activity remained significantly decreased and may account for the high incidence of infectious morbidity seen during this immediate post UCBT period.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482939     DOI: 10.1038/sj.bmt.1701921

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

1.  Pre-birth selection of umbilical cord blood donors.

Authors:  Patrizia Urciuoli; Simona Passeri; Francesca Ceccarelli; Barbara Luchetti; Aldo Paolicchi; Simone Lapi; Francesca Nocchi; Roberta Lamanna; Mariacarla Iorio; Renato Vanacore; Alessandro Mazzoni; Fabrizio Scatena
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

2.  Autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Authors:  Li Su; Juan Xu; Bing-Xin Ji; Sui-Gui Wan; Cong-Yan Lu; Hui-Qing Dong; Yue-Yi Yu; Dao-Pei Lu
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

3.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivors.

Authors:  Nancy Bunin; Trudy Small; Paul Szabolcs; K Scott Baker; Michael A Pulsipher; Troy Torgerson
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-17       Impact factor: 5.742

4.  Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Jan Joseph Melenhorst; Xin Tian; Dihua Xu; Netanya G Sandler; Philip Scheinberg; Angelique Biancotto; Priscila Scheinberg; John Phil McCoy; Nancy F Hensel; Zach McIver; Daniel C Douek; Austin John Barrett
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

5.  Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods.

Authors:  Steven A Dezell; Yong-Oon Ahn; Jan Spanholtz; Hongbo Wang; Matthew Weeres; Scott Jackson; Sarah Cooley; Harry Dolstra; Jeffrey S Miller; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-07       Impact factor: 5.742

6.  Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease.

Authors:  Amy Beres; Richard Komorowski; Masahiko Mihara; William R Drobyski
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

Review 7.  Immunotherapy for pediatric cancer.

Authors:  Stephan A Grupp; Michael Verneris; Paul M Sondel; Laurence J N Cooper
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

8.  Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease.

Authors:  Xiao Chen; Sanja Vodanovic-Jankovic; Bryon Johnson; Melissa Keller; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2007-08-10       Impact factor: 22.113

Review 9.  The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells.

Authors:  Michael R Verneris; Jeffrey S Miller
Journal:  Br J Haematol       Date:  2009-10       Impact factor: 6.998

10.  Association of serum interleukin-7 levels with the development of acute graft-versus-host disease.

Authors:  Robert M Dean; Terry Fry; Crystal Mackall; Seth M Steinberg; Fran Hakim; Daniel Fowler; Jeanne Odom; Jason Foley; Ronald Gress; Michael R Bishop
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.